Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family
11.10.2019 05:00:00 EEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/
Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation)
This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability.
Development Background
Advanced process control systems improve product yield and reduce energy consumption by maintaining temperature, flow rate, pressure, and other process variables within a set range and keeping them as close as possible to their optimal values, even for production processes whose parameters are not easily controlled by conventional control systems. Such advanced control systems are increasingly used in facilities such as oil refineries, petrochemical plants, chemical plants, and natural gas liquefaction trains. Advanced control solutions are attracting considerable interest due to their high economic value.
Multivariable advanced control systems determine the optimal value for plant independent variables. The optimal values are calculated based on information such as feedstock quality and prices, product specifications and prices, and energy costs. In a dynamically changing market, an advanced control system optimizes the operation of a plant in real time based on changes in raw material properties, product demand, and operating conditions.
Using our advanced control technology and KBC’s industry knowledge and simulation technology, we are able to perform highly accurate dynamic real-time optimization using rigorous models, in response to dynamically changing plant and market conditions.
Features
Dynamic Real Time Optimizer calculates the optimal values for plant independent variables with a high level of accuracy and was developed based on KBC’s Petro-SIMTM process simulation platform, which includes functions for online use. This solution acquires data through online connections to control systems and plant information management systems (PIMSs) and carries out case study simulations to generate rigorous models and calculate additional inferred properties. Based on these models and operating conditions, the optimal values are calculated by applying mathematical programming*1, and implemented online by the advanced control system.
1. Multi-unit optimization based on simulations performed using rigorous models
With large-scale applications, advanced control systems need to be able to quickly process huge amounts of data. Advanced control and optimization systems must have the processing speed needed to calculate the optimal values for such large applications. However, commercially-available products today are only suitable for small- to medium-size applications and can only optimize the control of individual process units. Yokogawa’s Platform for Advanced Control and Estimation*2 is capable of high-speed processing and can collectively control large-scale applications across processes. Using this suite as its operating platform, Dynamic Real Time Optimizer achieves multi-unit optimization and control. Also, as it makes use of KBC’s simulation technologies, the Dynamic Real Time Optimizer software can obtain optimal values with high accuracy even with reaction processes that demonstrate non-linear characteristics.
2. Integrated solution with improved maintainability
The performance of advanced control and optimization systems tends to degrade over time due to changes in operating conditions, catalyst activity changes, and the aging of facilities. Dynamic Real Time Optimizer is designed to maintain advanced control performance even as a plant changes, by using an online Petro-SIM model. The structure of this solution makes it easy to maintain advanced control and optimization systems, thus enabling operators to achieve optimal performance with nearly no change in maintenance workload.
*1 A method for determining the appropriate approach within a given range of rules, using mathematical models and computers
*2 A software suite with the following functionality:
- Multivariable model predictive control (the control of multiple variables based on predictions made using models of the dynamic characteristics of plant responses)
- Soft sensing for estimating quality in real time based on temperature, flow rate, pressure, and other process values
- Customization of calculations
Major Applications
Advanced control of continuous plant processes in the oil, petrochemical, chemical, gas, and other industries
For more information
About OpreX
OpreX is the comprehensive brand for Yokogawa’s industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa’s IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. Platform for Advanced Control and Estimation, an OpreX Asset Operations and Optimization family solution in the OpreX Transformation category, delivers operational excellence throughout an enterprise’s activities, from production through to supply chain optimization and risk and business management.
With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com.
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005009/en/
Contact information
Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom